国产人白细胞干扰素治疗慢性乙型肝炎的近期疗效观察

Short-term Observation on the Effect of Human Leukocyte Interferon in Treating Chronic Hepatitis B

对44例HBsAg、HBeAg和抗-HBc持续阳性的慢性乙型肝炎患者随机分为两组:一组im α-干扰素(1～3)×10~6U/d,总剂量40×10~6U,并联用胸腺肽20mg/d:静脉滴注;一组对照。疗程结束后评价,其近期有效(HBeAg阴转、ALT正常)率:干扰素组77.27%(17/22)明显优于对照组22.72%(5/22),差异有高度显著性(P<0.01)。未见干扰素的严重副反应。

Fourty-four adult chronic hepatitis B patients accompanied bypersistently positive, HBsAg, HBeAg and anti-HBc were assigned randomly either to receive recombinant human α-interferon (injections of(1-3)×10~6U/d)or to serve as unterated controls from Apr. 1989 to May 1990. After 40d follow up evaluation, 17 of the 22 treated patients but only 5 of the 22 controls had lost HBeAg and had recovered to normal ALT levels (77.27% VS. 22.72%, P<0.01). Serious side-effects were not observed in 22 patients treated with α-interferon.